PRAC opens Article 31 review of all injectable iron products over phosphate and bone risks

What happened

On 12 November 2026, EMA announced that its safety committee, PRAC, has opened an Article 31 review of all injectable iron medicines. The review covers two adverse outcomes, hypophosphataemia (low blood phosphate) and osteomalacia (softening of the bones). It also asks a third question: whether the risk-minimisation measures currently in place are effective.

The record describes the review as covering all injectable iron products, so it is not framed around a single product or marketing-authorisation holder. The records do not say which active substances or products are in scope, what data PRAC has requested, or when it expects to report. Those details are not yet known and should be checked against the EMA referral page.

Why a referral, and why the third question matters

An Article 31 referral is a formal EU procedure used when a safety or quality concern may affect the Union's interests, often because products are authorised in several member states. PRAC assesses the issue and issues a recommendation. That recommendation then goes through the usual EU decision-making steps and can lead to changes across all affected authorisations. Possible outcomes range from no change to updated product information, additional risk-minimisation measures, or restrictions.

The notable feature here is that the review does not stop at asking whether the risks exist. It also asks whether existing risk-minimisation measures work. That points to an evaluation of the measures themselves, not only the underlying safety data. For PV teams, this is a reminder that routine risk-minimisation, such as label wording and communications to prescribers, can be tested against real-world outcomes. If the committee concludes the measures fall short, the remedy could be a different or stronger set of measures rather than just a new warning.

What PRAC is likely to examine

The records give only the scope: hypophosphataemia, osteomalacia and the effectiveness of current measures. Beyond that, any account of what PRAC will look at is a general expectation, not reported fact. In a review like this, committees typically draw on spontaneous reports, published literature, clinical data and information supplied by marketing-authorisation holders. Whether this review follows that pattern, and whether it compares products within the class, has not been stated.

Hypophosphataemia can be asymptomatic and may be picked up only through laboratory testing. Osteomalacia can develop over a long period. Both features make case ascertainment and causality assessment difficult in spontaneous reporting. Teams reviewing their own data should expect that follow-up quality, such as phosphate measurements, duration of treatment and clinical course, will matter as much as case counts.

Who is affected

Every holder of an authorisation for an injectable iron product should assume it falls within the review's scope until EMA's procedural documents say otherwise. QPPVs should also expect requests for information, and possibly a tight timetable for responding, as is normal in referrals.

Beyond holders, the outcome would matter to prescribers and to patients receiving intravenous iron. No change to prescribing or patient management has been announced, and nothing in the records suggests one. It would be premature to treat the opening of a review as a finding of harm.

Context from the wider vigilance picture

Other items from the same week show how differently safety issues surface. In the US, FDA published early alerts on Intersurgical breathing systems, where a manufacturing shortfall in bonding solvent may let connectors detach, and on Arrow hydrophilic-coated guidewires and catheters, where the coating may detach. Health Canada listed a Type I recall of a Merit Medical sheath and dilator after four complaints, and the Dutch inspectorate IGJ published a field safety notice on an audiometer after two reports. Separately, a recall of a sexual enhancement product over undeclared sildenafil and acetaminophen noted that no adverse events had been reported.

These are different products and different mechanisms, and none is linked to the iron review. What they share is that action followed a small number of reports or a manufacturing finding. The iron review is different: it is a class-wide, committee-led assessment of a recognised risk and of the controls around it.

Two other EU items bear indirectly on how such work gets done. EMA published a page on AI in medicines regulation with a timeline of milestones from 2021 to August 2026, and the EU and Singapore agreed a working arrangement to exchange information on medicines and medical devices. The records do not connect either to this review.

What to watch

Watch for the review's scope and timetable on the EMA referral page, any list of questions for marketing-authorisation holders, and the PRAC recommendation. The key unknown is whether PRAC will find the current measures adequate. Until then, the safest approach is to strengthen your own evidence on both conditions.